Greetings from MyCancerHaven!
We wanted to update you on our recent activities.
Here are the latest posts last week:
Blogs :
Insights on REMS Programs and Strategies for Delivering Effective Patient Care.
Insights from the AURIGA Trial in Multiple Myeloma.
Impact of T-Cell Affinity in Bispecific Therapy for Relapsed/Refractory Multiple Myeloma.
Dr. Corre on MRD negativity with D-VTd in newly diagnosed myeloma.
Dr. Usmani on Daratumumab Plus VRd for Newly Diagnosed Myeloma Patients
Dr. Chari on the Risks and Benefits of Earlier CAR T Use in Relapsed/Refractory Multiple Myeloma.
Management and Supportive Care for CRS and ICANS in GPRC5D Therapy.
Dr. Dhakal on Survival and Safety Outcomes With Cilta-Cel in Relapsed/Refractory Myeloma
Dr. Badros on the Efficacy of Daratumumab Plus Lenalidomide in Newly Diagnosed Multiple Myeloma
Dr. Usmani on the Challenges of Bispecifics and CAR T-Cell Therapies in Multiple Myeloma.
Also at MCH the News and Tweets never stop flowing!
Join Us at www.mycancerhaven.org
The Team @ MCH
Follow us on Facebook, Twitter (@My_Cancer_Haven), Instagram, YouTube, LinkedIn and TikTok
Note: Please do not reply to this e-mail as it is sent from an account that is not monitored. You can contact us by e-mail at contact@mycancerhaven.org.
We wanted to update you on our recent activities.
Here are the latest posts last week:
Blogs :
Insights on REMS Programs and Strategies for Delivering Effective Patient Care.
Insights from the AURIGA Trial in Multiple Myeloma.
Impact of T-Cell Affinity in Bispecific Therapy for Relapsed/Refractory Multiple Myeloma.
Dr. Corre on MRD negativity with D-VTd in newly diagnosed myeloma.
Dr. Usmani on Daratumumab Plus VRd for Newly Diagnosed Myeloma Patients
Dr. Chari on the Risks and Benefits of Earlier CAR T Use in Relapsed/Refractory Multiple Myeloma.
Management and Supportive Care for CRS and ICANS in GPRC5D Therapy.
Dr. Dhakal on Survival and Safety Outcomes With Cilta-Cel in Relapsed/Refractory Myeloma
Dr. Badros on the Efficacy of Daratumumab Plus Lenalidomide in Newly Diagnosed Multiple Myeloma
Dr. Usmani on the Challenges of Bispecifics and CAR T-Cell Therapies in Multiple Myeloma.
Also at MCH the News and Tweets never stop flowing!
Join Us at www.mycancerhaven.org
The Team @ MCH
Follow us on Facebook, Twitter (@My_Cancer_Haven), Instagram, YouTube, LinkedIn and TikTok
Note: Please do not reply to this e-mail as it is sent from an account that is not monitored. You can contact us by e-mail at contact@mycancerhaven.org.
